IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com ASX Announcement Imugene Reports Further Complete Response and Partial Response in azer-cel Phase 1b Trial • New Complete Response (CR) in CAR T Naïve Cohort (Cohort...
Further Responses in azer-cel Phase 1b Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The trial continues to show promising results across multiple B-cell malignancies, with patient enrollment ongoing at various sites in the U.S. and Australia. These findings contribute to the growing clinical evidence supporting azer-cel's efficacy in treating patients with significant unmet medical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Story so far
Earlier from Imugene
- azer-cel BTKi Cohort Reports new Complete & Partial Response
- Third response in concurrent BTKi Cohort of azer-cel Trial
- $11.1 Million Placement Completed to Advance azer-cel
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- First Complete Response in Concurrent BTKi azer-cel Cohort
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene